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Abstract
There is significant need to identify novel prostate cancer drug targets because current hormone therapies eventually fail,
leading to a drug-resistant and fatal disease termed castration-resistant prostate cancer. To functionally identify genes that,
when silenced, decrease prostate cancer cell proliferation or induce cell death in combination with antiandrogens, we
employed an RNA interference-based short hairpin RNA barcode screen in LNCaP human prostate cancer cells. We identified
and validated four candidate genes (AKT1, PSMC1, STRADA, and TTK) that impaired growth when silenced in androgen
receptor positive prostate cancer cells and enhanced the antiproliferative effects of antiandrogens. Inhibition of AKT with a
pharmacologic inhibitor also induced apoptosis when combined with antiandrogens, consistent with recent evidence for
PI3K and AR pathway crosstalk in prostate cancer cells. Recovery of hairpins targeting a known prostate cancer pathway
validates the utility of shRNA library screening in prostate cancer as a broad strategy to identify new candidate drug targets.
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Introduction
Prostate cancer is the second leading cause of death from cancer
in American men with an estimated 217,730 new cases and more
than 32,000 deaths from the disease in 2010 [1]. While most early-
stage localized disease can be successfully treated by radiation
therapy and/or surgery, men who present with late-stage
metastatic cancer have a median survival of 3–7 years [2].
Furthermore, as many as 50% of patients treated with localized
disease will have local recurrence or distant metastases [2].
Current treatments for recurrent or metastatic disease include
targeting androgen receptor (AR) signaling through the use of
antiandrogens, such as bicalutamide, and drugs that prevent the
production of androgens in the testicles and adrenal glands, such
as gonadotropin-releasing hormone agonists and ketoconazole [3].
Although these current hormone therapies have initial effects in
reducing tumor burden, many men become resistant to these
therapies and develop castration-resistant prostate cancer (CRPC).
Men with CPRC have a poor prognosis and account for the
majority of deaths from the disease.
Men with CPRC often exhibit an increase in tumor androgen
receptor (AR) levels [4]. AR is a 110 kDa nuclear hormone
receptor that, in response to androgens, activates the transcription
of target genes involved in cell proliferation, differentiation, and
survival. In the prostatic luminal epithelium, AR regulates
differentiation and proliferation, and AR in prostate cancer cells
promotes cell cycle progression [5]. Previous work in our
laboratory shows that this increased AR level is necessary and
sufficient for the progression of prostate cancer to CRPC and its
function is essential to sustain tumor growth [6]. In addition to
CRPC, AR is expressed in nearly all prostate tumors and is
required for tumor maintenance [4,7,8]. Taken together, these
data suggest that AR signaling plays a critical role in hormone-
sensitive and CRPC and remains an important target for prostate
cancer therapeutics.
Identification of novel approaches to treat prostate cancer is an
area of intense therapeutic development. Recently abiraterone
acetate was approved based on a significant survival benefit in
patients with CRPC, and the novel antiandrogens, MDV3100 and
ARN-509, have been introduced with promising results; however
most tumors acquired resistance to these therapeutics [9–13]. To
date among chemotherapeutic agents only the taxanes docetaxel
and cabazitaxel have been shown to improve overall survival in
patients with CRPC [14–16]. As a result of the lack of agents that
sustain prostate cancer regression, new prostate cancer therapeutic
targets warrant further investigation.
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performed an unbiased multiplex shRNA screen that identified
modulators of prostate cancer cell viability in the presence of
bicalutamide. Four genes were validated to amplify the antipro-
liferative effects of anti-androgens in a prostate cancer cell line
when silenced. These data provide a general strategy to identify
prostate cancer drug targets.
Results
shRNA multiplex screen to identify modulators of
bicalutamide sensitivity
In order to identify genes that, when silenced, reduce cell
viability alone or in combination with the antiandrogen,
bicalutamide, we utilized a multiplex RNA interference-based
shRNA screen using a previously validated library (Figure 1A).
This technology employs uniquely barcoded shRNAs, expressed
from a retroviral vector, whose abundance after cell manipulation
can be identified by microarray [17]. The library was comprised of
,6,000 shRNAs targeting kinases, genes involved in cell cycle
regulation, and other genes known to be involved in cancer [17].
Analysis of expression data from 147 prostate tumor samples [18]
showed that 97% of the genes targeted by shRNAs in the library
are detected in at least 50% of the tumors. We utilized the
androgen receptor (AR)-positive LNCaP cell line for the screen
because they undergo growth arrest when treated with the AR
antagonist bicalutamide, grow relatively quickly, and are easily
infected with retrovirus (Figure S1). AR-negative PC3 human
prostate cancer cells served as a negative control of antiandrogen
sensitivity (Figure S1). Correlation between biological replicate
experiments in each cell line was high and did not change at later
time points or with bicalutamide treatment (Table S1).
Microarray analyses revealed that 23 probes, associated with 15
genes, were uniquely depleted in bicalutamide-treated LNCaP
cells, when compared to vehicle-treated cells (log2 bicalutamide/
vehicle #20.58, p#0.01) (Figure 1B, Table 1, and Figure
S2). No differences in depleted probes were observed across high
and low bicalutamide doses or early and late timepoints (day 8 or
day 21); therefore the data were combined for the analyses. Of the
15 genes identified, 11 were kinases (TTK, MAST3, CIT, PRKACG,
IGF1R, TSSK2, VEGFb, MAPKAPK5, ABL2, PLK2, and AKT1)
known to have functions in cell cycle regulation or cell viability
(Table 1). This high frequency of recovering kinase hits may be
relevant to the biology of prostate cancer cells but also likely
reflects a bias in the selection of genes for the shRNA library. The
remaining 4 gene hits have disparate functions: calmodulin
binding (STRN3), GTPase activation (RABGAP1), kinase adaptors
(STRADA), or involved with the proteasome (PSMC1). A parallel
screen was also performed in the androgen-independent cell line,
PC3, and, notably, none of the probes depleted in LNCaP cells
were depleted in PC3 cells in the presence of bicalutamide using
the same cut-off, providing evidence for specificity in antiandrogen
sensitive cells (Table S2).
Validation of candidate genes
To further examine these 15 candidate genes, we employed
independent knockdown technology (siRNA transfection using
siRNAs targeting sequences distinct from those used in the shRNA
screen) in a second AR dependent cell line (VCaP), which has been
shown to be resistant to bicalutamide but sensitive to the second
generation antiandrogen MDV3100 [19]. Silencing of the genes
was confirmed by qRT-PCR (Figure 2B). As a positive control,
VCaP cells were transfected with AR siRNAs and, as expected,
silencing of AR reduced cell viability (Figure 2A). Silencing of
AKT1, STRADA, PSMC1, and TTK enhanced the growth
inhibitory effect of MDV3100 in VCaP cells (Figure 2A, left
panel), consistent with the effects observed with bicalutamide in
the original screen in LNCaP cells. Interestingly, silencing AKT1
and PSMC1 in VCaP cells also decreased cell viability in the
absence of antiandrogen (Figure 2A, left panel).
We then examined the effect of silencing AKT1, STRADA,
PSMC1, and TTK on apoptosis, using PLK1 siRNAs as a positive
control. Silencing of AR, AKT, and STRADA in combination with
MDV3100 treatment induced VCaP cell apoptosis over control
siRNAs (NT) treated with MDV3100 (Figure 2A, right panel).
With the exception of AR, none of the siRNAs tested induced
apoptosis in the absence of MDV3100 (Figure 2A, right panel).
Although silencing of TTK in combination with MDV3100 did not
induce apoptosis over the NT cells with MDV3100, the
combination did reduce the number of viable cells more than
MDV3100 alone in the NT cells (Figure 2A, left panel). Taken
together, AKT, STRADA, and TTK siRNAs synergize with
MDV3100 to reduce VCaP cell viability. Whereas AKT1 and
STRADA silencing reduces cell viability, at least partially, due to
increased apoptosis when combined with MDV3100, TTK seems
to work through an alternative growth inhibitory mechanism.
Although PSMC1 did not score in the PC3 cells in the initial
shRNA library screen, siRNA knockdown of PSMC1 impaired
viability of PC3 cells, raising the possibility that these antiprolif-
erative effects may not be specific to AR-positive prostate cancer
cells (Figure S3). For this reason, we did not pursue further
characterization of PSMC1.
Overexpression of TTK is associated with increased
probability of biochemical recurrence
To explore whether AKT1, STRADA, and TTK are altered in
human prostate cancer, we assessed the copy number and
expression status of these genes in a previously-reported human
prostate cancer dataset [18]. Of the 218 prostate tumors, 34.4%
had reduced expression of STRADA, 18.3% exhibited overexpres-
sion of TTK, 11.7% either overexpressed or had reduced
expression of AKT1, and 15.6% of tumors overexpressed or had
amplified AR (Table 2). Overexpression was defined as z-score$2
and reduced expression was defined as z-score,2, compared to
expression in normal prostate samples. Unlike AR, STRADA, TTK,
and AKT1 showed little evidence of gene amplification or loss in
human prostate tumors. The large number of prostate tumors with
alterations in STRADA, TTK, and AKT1 expression led us to look
at their correlation with biochemical recurrence. Interestingly,
overexpression of TTK exhibited a significant association with
biochemical recurrence (p=0.003) (Figure 3). TTK expression
did not significantly correlate with the following clinical charac-
teristics: surgical margin, lymph node status, seminal vesicle,
Gleason score, treatment prostate specific antigen (PSA), mean
PSA, or extracapsular extension (Table S3).
Blocking AKT cooperates with bicalutamide to induce
LNCaP cell apoptosis
To further investigate the potential role of these genes as
therapeutic targets in prostate cancer, we turned to pharmaco-
logical inhibitors. We assessed the number of viable LNCaP cells
using an AKT1/2 inhibitor in the presence and absence of
bicalutamide. Treatment with bicalutamide or the AKT inhibitor
reduced the number of viable cells by 10% and 45%, respectively
(Figure 4A). In contrast, combining the compounds reduced cell
proliferation by 100% and induced apoptosis as shown by an
increase in PARP cleavage (Figure 4B). These data suggest that
Prostate shRNA Library Screen
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combination with antiandrogen therapy, consistent with recent
evidence using PI3K inhibitors [20].
Discussion
Current therapies for prostate cancer include antiandrogens
such as bicalutamide and MDV3100. Although nearly all patients
have initial responses to these drugs, many tumors become
resistant to these therapies, resulting in CRPC. Due to the
important role that AR plays in primary prostate cancer and
CRPC, AR remains a relevant therapeutic target. Identification of
novel approaches to treat prostate cancer, including the develop-
ment of combination therapies with antiandrogens, is an area of
therapeutic development. Therefore, we executed an unbiased
multiplex shRNA screen to identify modulators of prostate cancer
cell viability. Our goal was to identify genes that might be
exploited for novel targeted therapy.
From the shRNA screen and in vitro siRNA validation
experiments in an independent cell line, we identified and
validated AKT1, STRADA, and TTK as candidate genes that
synergize with antiandrogens (Figure 1 and Figure 2). Although
AKT1, STRADA, and TTK scored as inhibitors of LNCaP cell
proliferation in the context of bicalutamide, validation with
siRNAs in the same cell line revealed that they can decrease cell
viability in the absence of bicalutamide (Figure S4A). This effect
was specific to LNCaP and was not observed in AR-negative PC3
cells. One explanation for this difference in phenotype is the
strength of shRNA knockdown in the screen versus the siRNA in
the validation experiments, since siRNAs generally achieve greater
knockdown than the shRNAs at an MOI#0.5. Indeed, the
siRNAs did exhibit a high level of gene silencing in the validation
experiments (Figure S4B).
It will be of interest to understand the mechanism by which
inhibition of AKT1, STRADA or TTK enhances antiandrogen
activity. One possibility is through regulating AR-dependent
transcription but we failed to observe a decrease in mRNA levels
of AR or AR-target genes (TMPRSS2, FKBP5, NKX3.1,o rKLK3)
when these genes were silenced in LNCaP cells (data not shown).
Another possibility is disruption of signaling pathway crosstalk, as
illustrated by recent evidence for reciprocal negative feedback as
an explanation for the synergy observed with combined PI3K/AR
pathway inhibition [20].
TTK, also known as monopolar spindle 1 (Mps1), is a serine/
threonine and tyrosine kinase that has been implicated in the
maintenance of the spindle assembly checkpoint and is required
Figure 1. shRNA probes depleted or enriched in bicalutamide-treated LNCaP cells. (A) Schematic of shRNA screen. Details can be found in
the Materials and Methods section. (B) A heatmap was generated by clustering based on probes that were depleted or enriched (log2 bicalutamide/
vehicle #+/20.58 and a p-value#0.01) in the bicalutamide (0.4 uM and 1.0 uM)-treated LNCaP cells at T=1 and T=2 compared to the vehicle-
treated cells at the same timepoints. The shRNA target gene associated with each probe is indicated to the right of the heatmap. Target genes that
appear more than one time on the heatmap indicate that more than one probe scored for that gene.
doi:10.1371/journal.pone.0034414.g001
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is of particular interest since others have reported that reducing
levels of TTK sensitized human tumor cells to sub-lethal doses of
taxol, whereas nontumorigenic cells could not be sensitized to
taxol [23]. Here we find that that silencing TTK resulted in
sensitization of VCaP cells to a potent antiandrogen. The fact that
18% of human prostate tumors overexpress TTK and that these
tumors have a different clinical outcome suggests that TTK
inhibitors in combination with antiandrogens may be of interest.
STE20-related kinase adaptor alpha, or STRADA, is a
pseudokinase that is reported to be required for proper activity
of the tumor suppressor, liver kinase B1 (LKB1) [24]. STRADA is
required for function of the LKB1 tumor suppressor; therefore,
silencing of STRADA might be expected to promote tumorigenesis.
Our finding that STRADA exhibited reduced expression in a large
percent of human prostate cancers is consistent with a tumor
suppressor role (Table 2). However, it is possible that STRADA
has functions independent of LKB1/AMPK signaling that
promote growth inhibition in certain cellular contexts. The
potential role of STRADA in prostate cancer progression and
the possibility of LKB1/AMPK-independent functions warrant
additional attention.
Akt1 is a serine-threonine kinase that relays signals from
phosphatidylinositol 39 kinase (PI3K) by its phosphorylation of
downstream targets and deregulation of this pathway is known to
contribute to prostate cancer progression [25,26]. It is well known
that the PI3K/Akt pathway plays an important role in prostate
cancer cell viability and tumorigenesis and it is being currently
being investigated as a therapeutic target [27,28]. Previous reports
have shown that the AKT/PI3K pathway regulates LNCaP cell
growth and that expression of constitutively active AKT can block
bicalutamide-induced growth inhibition [27,29,30]. Furthermore,
Akt1 has been demonstrated to interact with AR [31]. Loss of
function of the phosphatase and tensin homolog (PTEN), a
negative regulator of the PI3K/AKT pathway, occurs in at least
50% of advanced human prostate cancer [32–34]. This loss of
Pten function results in increased expression of phosphorylated
Akt and subsequent activation of downstream targets involved in
cell survival and proliferation [35,36]. Inhibition of AKT using
siRNAs or a pharmacological inhibitor induced apoptosis in
combination with bicalutamide or MDV3100 in AR-dependent
prostate cancer cells (Figure 2A, right panel and Figure 4). As
a result of the reported roles of Akt1 in prostate cancer
tumorigenesis, the PI3K/AKT pathway is being closely examined
as a therapeutic target [25]. Our data support the use of Akt
inhibitors in combination with antiandrogens to treat prostate
cancer.
Materials and Methods
Cell culture and antiandrogens
Human prostate carcinoma cell lines (LNCaP, PC3, and VCaP)
and human embryonic kidney cells (293T) were purchased from
American Type Culture Collection (Manassas, VA) and were
maintained below 20 passages in the laboratory. Cells were
cultured according to ATCC guidelines. No abnormalities were
observed in growth or morphology for any cell line under their
respective growth conditions. Bicalutamide was purchased from
AstraZeneca Pharmaceuticals LP (Wilmington, DE) and
MDV3100 was synthesized at Memorial Sloan-Kettering Cancer
Center by the Organic Synthesis Core Facility [19] .
Preparation of short-hairpin RNA library DNA and virus
A plasmid library (pLMP) expressing ,6,000 short-hairpin
RNAs (shRNAs) targeting kinases, genes involved in cell cycle
regulation, and other genes known to be involved in cancer was
used in the current screen [17]. The pooled plasmid library was
amplified in TOP10 electrocompetent cells (Invitrogen, Carlsbad,
Table 1. Probes depleted in bicalutamide-treated LNCaP cells.
shRNA target gene Description Probes scored
* log2 (Bic/Veh)
** p value
STRN3 Striatin, calmodulin binding protein 3, cell cycle protein 2 21.527 21.008 0.0037 0.0073
STRADA STE20-related kinase adaptor alpha 1 21.197 0.0003
TTK Ser/Thr/Tyr kinase, cell cycle regulated 3 21.014 21.018 20.991 0.0039 0.0040
0.0073
MAST3 Microtubule associated Ser/Thr kinase 3 1 20.901 0.0009
PSMC1 Proteasome 26S subunit ATPase 1 2 20.900 20.880 0.0048 0.0060
CIT Citron, Rho-interacting, Ser/Thr kinase 21 2 20.802 20.815 9.12E-05 0.0001
RABGAP1 GTPase-activating protein of RAB6A, microtubule/
centrosome function
1 20.791 0.0035
PRKACG Gamma form of Protein Kinase A catalytic subunit 1 20.758 0.0043
IGF1R Insulin-like growth factor 1 receptor 2 20.716 20.681 0.0047 0.0091
TSSK2 Testes-specific serine kinase 2 1 20.666 0.0045
VEGFb Vascular endothelial growth factor beta 2 20.660 20.594 0.0015 0.0026
MAPKAPK5 Mitogen-activated protein kinase-activated protein
kinase 5
1 20.645 0.0095
ABL2 V-abl Abelson murine leukemia viral oncogene
homolog 2, tyrosine kinase
1 20.621 0.0047
PLK2 Polo-like kinase 2, Ser/Thr kinase 2 20.598 20.584 0.0045 0.0085
AKT1 Ser/Thr kinase 1 20.594 0.0041
*Number of probes that had a log2 value #20.58.
**Bic, bicalutamide; Veh, vehicle.
doi:10.1371/journal.pone.0034414.t001
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transformants per hairpin. Virus was produced in 293FT cells
by co-transfecting the pUMVC3-Gag-Pol expression vector
(Addgene, Cambridge, MA), VSVG pantropic envelope (Ad-
dgene), and the shRNA library DNA isolated above.
shRNA interference screen
The shRNA interference screen is depicted in Figure 1A.
LNCaP and PC3 cells were infected with the 6K shRNA pooled
library virus (MOI#0.5) in triplicate to generate a total of 6
million infected cells per replicate, per cell line. Infection of target
cells at MOI#0.5 was confirmed by fluorescence microscopy and
fluorescence activated cell sorting (FACS) 48 h after infection.
LNCaP and PC3 cells were selected with 3 ug/ml puromycin and
the cells were counted and plated in growth media containing
0.4 uM bicalutamide, 1.0 uM bicalutamide, or vehicle (DMSO).
Cells were passaged, and bicalutamide and vehicle replenished,
every 4 days without allowing confluence. LNCaP and PC3 cells
from each replicate were harvested and cell pellets were flash
frozen and stored at 280uC at multiple time-points during the
screen. Cells were harvested 48 h after infection (T=0), and after
8 days (T=1) and 21 days (T=2) of exposure to vehicle or
bicalutamide.
Microarray
Genomic DNA was extracted from cells using standard
conditions. Barcodes and half-hairpins from the library plasmid
DNA (originally used to make the virus) and LNCaP and PC3 cell
genomic DNA isolated above were PCR amplified using the
following primers: 59-TAGTGAAGCCACAGATGTA-39 and 59-
AAAGCGCATGCTCCAGACTGCC-39. The PCR products
were subject to gel electrophoresis and the resulting 350 bp bands
were gel purified using the QIAEX II gel extraction kit (QIAGEN,
Valencia, CA).Purified DNA fragments (1.5 ug) from LNCaP or
PC3 cells were labeled and microarray hybridization was carried
out using custom Agilent chips as previously described [17].
Microarray data analysis
Affymetrix exon array data from 147 tumor samples [18] were
used to determine expression levels of shRNA target genes
Figure 2. Silencing of a subset of genes inhibited VCaP proliferation and induced apoptosis. Candidate target genes from LNCaP screen
probes that were depleted in the presence of bicalutamide were selectively targeted using siRNAs. (A, left panel), VCaP cells were transfected with
siRNAs that scored in the LNCaP drug screen and were incubated with 1 uM MDV3100 or vehicle, and the number of viable cells was measured 6 days
post-treatment. (A, right panel), VCaP cells were transfected and treated as in (A, left panel) except Caspase 3/7 activity was measured after 3 days of
treatment. PLK1 siRNA transfection was used as a positive control. Dashed lines indicate the level of growth inhibition or apoptosis induced by
MDV3100, for comparison. NT, non-targeting siRNA. (B) Gene silencing (10–50%) was confirmed by RT-qPCR 6 days post-transfection of VCaP cells
with the siRNA SMARTpools. Reactions were done in triplicate and normalized to RPL27 for each cDNA and then normalized to vehicle-treated NT.
Standard error of the mean was calculated. Bic, bicalutamide.
doi:10.1371/journal.pone.0034414.g002
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normalized intensity greater than 50 were considered as detected.
Agilent Feature Extractor software was used to scan microarray
images. Feature Extractor normalized Cy3 intensity for each array
was compiled and all further processing was performed using the
statistical software package R 2.8.1. Quality was assessed
throughout using principal component analysis and more formally
by comparing the interquartile range across arrays. Samples with a
log2 transformed interquartile range less than 6 were considered
outliers and not considered in further analysis. When duplicate
samples (technical replicates) remain, the most recent replicate of
each was used. The remaining samples were subject to quantile
normalization. Probes corresponding to hairpins not present in the
library were used as negative controls. The 95th percentile signal
intensity of negative controls was used as the background measure
and was estimated from pre-selection (T=0) samples. Probes were
removed from further analysis when they did not exceed the
sample specific background estimate on a majority of pre-selection
samples. Statistical testing was performed to identify hairpins
whose abundance varied over time in untreated samples. The time
course analysis implemented in the extraction of differential gene
expression (EDGE) software was used for this analysis [37]. To
identify hairpins where abundance was associated with the
presence of bicalutamide the linear models for microarray library
in R 2.8.1 was used [38]. Specifically, a linear model was
constructed with terms for treatment, time point, and replicate.
This model was fit to each probe, and fold changes and p-values
corresponding to the treatment effect were used to identify probes
of interest. The two bicalutamide doses (0.4 uM and 1.0 uM) and
the two timepoints collected post-selection (T=1 and T=2) were
combined for the analysis to increase statistical power. Significant
differences between bicalutamide doses and timepoints were not
observed. Candidates that had an abundance change that was
associated with the presence of bicalutamide were selected that
resulted in a log2 bicalutamide/vehicle #20.58 and a p-
value#0.01. Visualization of candidates was performed with
Figure 3. Higher TTK expression is associated with biochemical recurrence. Kaplan Meier plot of the risk of biochemical recurrence in
patients (n=131) with TTK overexpressing prostate tumors (n=20; green line) versus those without TTK overexpressing (n=111; blue line) tumors
(p=0.003, log-rank test).
doi:10.1371/journal.pone.0034414.g003
Table 2. Candidate gene expression and alterations in human prostate tumors.
Gene
% of prostate tumors with
alteration (n=218) mRNA Upregulation mRNA Downregulation Amplification Deletion
AR 15.1% 18
* 41 5 0
AKT1 11.9% 12 14 0 0
STRADA 36.2% 4 74 1 0
TTK 18.4% 33 4 0 3
*4 of the samples with upregulated AR mRNA also had AR amplification.
doi:10.1371/journal.pone.0034414.t002
Prostate shRNA Library Screen
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MIAME compliant. All raw data has been deposited in GEO
(series ID GSE32261).
Cell viability and apoptosis assays
ON-TARGETplus non-targeting (NT) siRNA and siRNA
SMARTpools targeting ABL2, AKT1, AR, CIT, IGF1R, MAP-
KAPK5, MAST3, PLK2, PRKACG, PSMC1, RABGAP1, STRADa
(STRADA), STRN3, TSSK2, TTK, and VEGFb were purchased
from Thermo Fisher Scientific (Lafayette, CO). siRNAs targeting
PLK1 were used as a positive control for apoptosis and were
obtained from the MSKCC High-Throughput Drug Screening
Facility. Log phase LNCaP, PC3, and VCaP cells were transfected
with 100 nM siRNA using DharmaFECT (Thermo Fisher
Scientific). Cell viability was determined 3 and 6 days after
incubation with bicalutamide (1 uM), MDV3100 (1 uM), or
vehicle using the Cell Titer-Glo Luminescent cell viability assay
(Promega). Apoptosis was assayed using the Caspase-Glo 3/7
assay (Promega) and values were normalized to the Day 3 Cell
Titer-Glo assay. Assays were performed in triplicate and standard
errors of the mean are reported. Cell proliferation assays were also
performed by incubating cells with vehicle (DMSO), bicalutamide
(1 uM), AKT inhibitor (1 uM) (MERCK, Whitehouse Station,
NJ), or a combination of bicalutamide and AKT inhibitor and
counting the cells. Experiments were conducted in triplicate and
the standard deviations are reported.
Immunoblotting
Cell lysates for Western blot analyses were prepared using
standard RIPA buffer. The antibodies used for western blot
analysis and immunohistochemistry were pAkt Ser473 (Cell
Signaling Technology, 1:1000 dilution), Akt (Cell Signaling
Technology, Danvers, MA, 1:1000 dilution), pS6 Ser235/236
(Cell Signaling Technology, 1:1000 dilution), PARP (Cell
Signaling Technology, 1:1000 dilution), and Actin (Cell Signaling
Technology, 1:1000 dilution).
Quantitative reverse transcription-PCR
LNCaP, PC3, and VCaP cells subject to siRNA transfection
were harvested 4 days or 7 days post-transfection to monitor
knockdown of the target gene(s) by quantitative reverse transcrip-
tion-PCR (qRT-PCR) (see Table S4). Reactions were done in
triplicate and normalized to RPL27 for each cDNA and then
normalized to vehicle-treated NT. Standard error of the mean was
calculated.
Biochemical recurrence
The gene expression and copy number status of STRADA, TTK,
AR, AKT1, SKT22B, PSMC1, and PRKACG in primary and
metastatic human prostate cancer (n=218) was determined by
using the MSKCC Cancer Genomics Pathway Portal [18].
Twenty of the 131 tumors had TTK over-expression defined as
z-score$2. Cases were classified as TTK high and TTK normal/
low. The probability of freedom from biochemical recurrence
following radical prostatectomy (BCR defined as .0.2 ng/ml and
rising prostate specific antigen) was reported using Kaplan-Meier
analysis. P-value was calculated using the log-rank test.
Supporting Information
Figure S1 Bicalutamide inhibited LNCaP cell prolifer-
ation. After infection with the shRNA library and puromycin
selection (A) LNCaP and (B) PC3 cells were counted and plated in
growth media containing 0.4 uM bicalutamide, 1.0 uM bicaluta-
mide, or vehicle (0 uM). Cells were counted and passaged every 4
days to monitor growth in response to vehicle and bicalutamide.
Results are presented as the average number of viable cells (top
panels) or as the percent of viable bicalutamide-treated cells
compared to vehicle-treated cells (bottom panels) at each time
point over the 21 day time course for each drug treatment 6
standard error of 3 replicate experiments.
(TIF)
Figure 4. Akt1/2 inhibitor cooperated with bicalutamide to induce LNCaP cell apoptosis. (A) Number of viable LNCaP cells treated over 5
days with vehicle, bicalutamide (1 uM), Akt1/2 inhibitor (1 uM), or a combination of bicalutamide and AKT inhibitor. (B) Apoptosis was measured in
LNCaP cells by immunoblotting using a PARP antibody in LNCaP cells treated as in (A). Inhibition of phosphorylated Akt (pAkt (Ser473)) and
phosphorylated S6 (pS6) was also measured. Actin was used as a loading control.
doi:10.1371/journal.pone.0034414.g004
Prostate shRNA Library Screen
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34414Figure S2 shRNA probes depleted in LNCaP cells.
Boxplots of the relative abundance of probes in the vehicle and
bicalutamide-(drug) treated LNCaP cells. Data from T=2 and
T=3 were combined for the vehicle or bicalutamide-treated
boxplots. Both bicalutamide doses (0.4 uM and 1.0 uM) were also
combined for the drug boxplots. The name of the shRNA probes
appear in parentheses next to the target gene name above each
boxplot.
(TIF)
Figure S3 Silencing of PSMC1 inhibited PC3 cell
proliferation. (A) PC3 cells were transfected with siRNAs,
treated with 1 uM bicalutamide or vehicle, and the number of
viable cells was measured 6 days post-treatment. Only siRNAs that
inhibited VCaP cell proliferation from Figure 2 are shown. The
dashed line indicates the level of growth inhibition induced by
bicalutamide, for comparison. (B) Gene silencing was confirmed
by RT-qPCR 6 days post-transfection of VCaP cells with the
siRNA SMARTpools. Reactions were done in triplicate and
normalized to RPL27 for each cDNA and then normalized to
vehicle-treated NT. Standard error of the mean was calculated.
Bic, bicalutamide.
(TIF)
Figure S4 Silencing of a subset of genes inhibited
LNCaP proliferation. Candidate target genes from LNCaP
screen probes that were depleted in the presence of bicalutamide
were selectively targeted using siRNAs. (A) LNCaP cells were
transfected with siRNAs, treated with 1 uM bicalutamide or
vehicle, and the number of viable cells was measured 6 days post-
treatment. Only siRNAs that inhibited LNCaP cell proliferation
are shown. The dashed line indicates the level of growth inhibition
induced by bicalutamide, for comparison. (B) Gene silencing was
confirmed by RT-qPCR 6 days post-transfection of LNCaP cells
with the siRNA SMARTpools. Reactions were done in triplicate
and normalized to RPL27 for each cDNA and then normalized to
vehicle-treated NT. Standard error of the mean was calculated.
Bic, bicalutamide. NT, non-targeting siRNA.
(TIF)
Table S1 Correlation among replicate experiments.
Correlation between biological replicate microarray experiments
in the LNCaP and PC3 cells 48 h after infection or after culture
for 8 or 21 days in vehicle or bicalutamide. For the correlation
analysis 0.4 uM and 1.0 uM bicalutamide doses were combined.
(DOCX)
Table S2 Probes depleted in bicalutamide-treated PC3
cells. The number of microarray probes that had a log2 value
#20.58 (probes scored) in the PC3 cells. Bic, bicalutamide; Veh,
vehicle
(DOCX)
Table S3 Tumor TTK expression correlation with
clinical characteristics. TTK expression in 131 prostate
tumors and its correlation with surgical margin, lymph node
status, seminal vesicle, Gleason score, treatment prostate specific
antigen (PSA), mean PSA, or extracapsular extension. TTK
overexpressed samples were defined as z-score$2 and TTK not
overexpressed samples were defined as z-score,2.
(DOCX)
Table S4 Primers used for quantitative reverse tran-
scription-PCR. Primers were used for validation of the mRNA
expression levels of the genes defined in Table 1.
(DOCX)
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